Journal
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
Volume 29, Issue -, Pages 434-443Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jgar.2021.10.021
Keywords
Lefamulin; Moxifloxacin; Microbiology; Community-acquired bacterial pneumonia; CABP; Efficacy
Categories
Funding
- Nabriva Therapeutics plc (Fort Washington, PA, USA)
Ask authors/readers for more resources
Lefamulin is an effective antibiotic for the treatment of community-acquired bacterial pneumonia with good microbiological efficacy, suitable for both intravenous and oral administration.
Objectives: Lefamulin, a pleuromutilin antibiotic approved for community-acquired bacterial pneumonia (CABP), was evaluated for microbiological efficacy in a prespecified pooled analysis of LEAP 1 and 2 phase 3 clinical trial data in patients with CABP. Methods: In LEAP 1, adults (PORT risk class III-V) received intravenous (IV) lefamulin 150 mg every 12 h (q12h) for 5-7 days or moxifloxacin 400 mg every 24 h (q24h) for 7 days, with optional IV-to-oral switch. In LEAP 2, adults (PORT II-IV) received oral lefamulin 600 mg q12h for 5 days or moxifloxacin 400 mg q24h for 7 days. Primary outcomes were early clinical response (ECR) at 96 +/- 24 h after treatment start and investigator assessment of clinical response (IACR) 5-10 days after the last dose. Secondary outcomes included ECR and IACR in patients with a baseline CABP pathogen (detected via culture, urinary antigen testing, serology and/or real-time PCR).Results: Baseline CABP pathogens were detected in 709/1289 patients (55.0%; microbiological intention to-treat population). The most frequently identified pathogens were Streptococcus pneumoniae (61.9% of patients) and Haemophilus influenzae (29.9%); 25.1% had atypical pathogens and 33.1% had polymicrobial infections. Pathogens were identified most frequently by PCR from sputum, followed by culture from respiratory specimens. In patients with baseline CABP pathogens, ECR rates were 89.3% (lefamulin) and 93.0% (moxifloxacin); IACR success rates were 83.2% and 86.7%, respectively. Results were consistent across CABP pathogens, including drug-resistant isolates and polymicrobial infections.Conclusion: Lefamulin is a valuable IV and oral monotherapy option for empirical and directed CABP treatment in adults.(c) 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available